Print Page     Close Window     
MESOBLAST LTD filed this Form 6-K on 11/07/2018
Entire Document

Slide 33

CY 2018 Corporate Milestones MSC-100-IV for Acute Graft versus Host Disease Successfully met Day 28 primary end point pediatric Phase 3 trial (Q1 CY18) Day 100 survival/safety data pediatric Phase 3 trial (Q2 CY18) Day 180 survival/safety data pediatric Phase 3 trial (Q3 CY18) FDA meetings (Q4 CY18) MPC-150-IM for Advanced and End-Stage Heart Failure Phase 2b trial full 12 month database lock in end-stage heart failure patients with LVADs (Q3 CY18) Phase 2b results presentation expected at major cardiovascular conference (Q4 CY18) End of study safety, efficacy and key clinical outcomes will be presented by independent investigators as a late-breaking presentation at the 2018 Scientific Sessions of the American Heart Association Phase 3 trial in advanced heart failure enrollment completion (H2 CY18) MPC-06-ID for Chronic Low Back Pain Phase 3 trial completed enrollment (Q1 CY18) Completed non-dilutive transactions for commercialization of MSC-100-IV (remestemcel-L) Establish regional strategic and commercial partnerships Establish global commercial partnerships (China, Japan, Europe)

Copyright © 2015 Mesoblast Inc.